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Summary 
Acute organ transplant rejection is characterized by a heavy lymphocyte infiltration. We have 
previously shown that alterations in the graft endothelium lead to increased lymphocyte traffic 
into the graft.  Here, we demonstrate that lymphocytes adhere to the endothelium of rejecting 
cardiac transplants, but not to the endothelium of syngeneic grafts  or normal hearts analyzed 
with the in vitro Stamper-Woodruff binding assay. Concomitant with the enhanced lympho- 
cyte adhesion, the cardiac endothelium begins to de novo express sialyl Lewis  a and sialyl Lewis  x 
(sLea and sLex) epitopes, which have been shown to be sequences of L-selectin counterrecep- 
tors. The endothelium of allografts,  but not that of syngeneic grafts or normal controls, also re- 
acted with the L-selectin-immunoglobulin G fusion protein, giving further proof of inducible 
L-selectin counterreceptors. The lymphocyte adhesion to endothelium could be significantly 
decreased  either by treating the  iymphocytes with  anti-L-selectin  antibody HRL-1,  or by 
treating the tissue  sections with sialidase  or anti-sLea or anti-sLex monoclonal antibodies. Fi- 
nally, we synthetized enzymatically several members of the sLex family oligosaccharides and 
analyzed their ability to block lymphocyte adhesion to cardiac endothelium. The monovalent 
sLex (a tetramer), divalent sLex (a decamer), and tetravalent sLex (a 22-mer) could all signifi- 
cantly reduce lymphocyte binding,  but the  inhibition by the  tetravalent sLex-construct was 
clearly superior to other members of the sLex family. The crucial control oligosaccharides, sia- 
lyl lactosamines lacking fucose but being otherwise similar to the members of sLex family, had 
no effect on lymphocyte binding. 
L 
Ymphocyte extravasation is initiated by the interaction 
of members of the selectin family and their oligosac- 
charide-containing counterreceptors (1-5). L-selectin is solely 
expressed  on  leukocytes  and  recognizes  an  endothelial 
counterreceptor that is at least c~2,3-sialylated, c~l,3/4-fuco- 
sylated, and contains sulfate group(s) (6-10). Three mucin- 
like  heavily O-glycosylated proteins,  GlyCAM-1,  CD34, 
and  MAdCAM-1,  which  participate  in  the  L-selectin- 
dependent adhesion, have been cloned (11-14).  High en- 
dothelial cells in peripheral lymph nodes express sialyl Lewis  a 
and  sialyl  Lewis  x  (sLea  and  sLex,  respectively)  1 epitopes 
*Abbreviations used in this paper: sLea, sialyl  Lewisa; sLex,  sialyl  LewisX;  sLN, 
sialyl lactosamine. 
(15-17), which are parts of the L-selectin counterreceptor. 
The endothelial cells in several other locations are sLea and 
sLex negative, but inflammatory stimuli can induce previ- 
ously negative  endothelium to  express these  oligosaccha- 
ride structures de novo (18). We have also shown that cul- 
tured endothelial cells possess the machinery to generate at 
least sLex, since they have several functional 0e2,3 sialyl- and 
c11,3  fucosyltransferases,  enzymes  involved  in  generating 
sLex from (poly)lactosamines (19). 
Heart transplant rejection is characterized by a heavy in- 
filtration of lymphocytes into the graft (20-22).  Here, we 
show that rat cardiac endothelium, which does not express 
sLea and sLex in normal animals, can be induced to express 
these  oligosaccharide  epitopes  during  transplant  rejection 
episodes.  This de novo expression of sialylated Lewis oli- 
1133  j. Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/95/10/1133/09  $2.00 
Volume 182  October 1995 1133-1142 gosaccharides leads  to  enhanced  lymphocyte  adhesion  to 
endothelium  in  a  sLea-,  sLex-,  and  L-selectin-dependent 
manner.  The  endothelium of rejected heart grafts, but not 
that  of normal  hearts  or  syngeneic  grafts,  stains  directly 
with  the  L-selectin-IgG fusion protein.  We have  synthe- 
tized mono-, di-, and tetravalent sLex oigosaccharides and 
their  corresponding  sialyl  lactosamine  (sLN)  constructs 
lacking fucose.  Our results show that the tetravalent sLex 
(a  22-mer  oligosaccharide)  is  superior in  inhibiting the 
L-selectin-dependent lymphocyte adhesion to heart endo- 
thelium compared to di- or monovalent sLex oligosaccha- 
rides (a deca- and tetramer, respectively). On the contrary, 
the  sLN oligosaccharides did not have  any effect on lym'- 
phocyte adhesion.  Taken  together,  these  data suggest that 
the upregulation of the endothelial expression of sLea and 
sLex is of crucial importance in the generation of L-selec- 
tin-dependent  lymphocyte  inflammation  in  the  rejecting 
cardiac allograft, and  that  soluble oligosaccharides can  in- 
hibit this process. 
Material and Methods 
Rats and Transplantations.  Inbred WF (R.T1 v) and DA (RT1 a) 
rat strains were carried in our own colony and regularly tested for 
intrastrain acceptance of cardiac and renal transplants, as well as 
for the absence of intrastrain mixed lymphocyte culture.  10-12- 
wk-old rats  were  used for the  transplantations, and a  modified 
microvascular technique was used (22). The DA hearts that were 
transplanted into WF recipients were allografts, WF grafts to WF 
and DA grafts  to DA served as syngeneic controls, and normal 
nontransplanted hearts served as controls. 
Stamper-Woodruff Binding Assay.  Syngeneic (DA to DA and 
WF  to  WF)  and  allogeneic (DA  to  WF)  transplants were  re- 
moved on day 3 after the transplantations. Small pieces of the re- 
moved hearts were  mounted in Tissue Tek medium  (Lab-Tek 
Productions, Naperville, IL) and snap-frozen in liquid nitrogen. 
8-~m-thick frozen sections were prepared within 1 h before the 
use of the sections in the lymphocyte-endothelium binding assay 
(23). 
Single-cell suspensions ofmesenteric lymph node lymphocytes 
were made by mechanical disaggregation in R.PMI 1640 medium 
(GIBCO  BRL,  Bethesda,  MD)  supplemented with  Hepes  (25 
raM) and 0.5% FCS and the cells were passed through a 50-~m 
pore size mesh. Lymphocyte purity was >99%,  and the popula- 
tion consisted of 80-90%  CD3-positive T  cells,  50-60%  CD4- 
positive  T  cells,  25-35%  CD8-positive  T  cells,  and  10-20% 
CD19-positive B  cells,  as analyzed by flow cytometric analyses 
and  immunoperoxidase  stainings  from  cytocentrifuge prepara- 
tions. 
3  X106  cells in 100  pA of the medium were plated on top of 
the tissue  sections using a wax pen circle to avoid escape of the 
fluid. The  sections were rotated horizontally on  a shaker at 60 
rpm for 30 rain at +4~  After incubation, the medium was gen- 
tly tapped away by an absorbent paper and the slides were fixed in 
1.5% cold glutaraldehyde overnight. The slides were stained with 
thionine for 30 rain. The excess thionine was gently washed away 
using PBS, and the slides were mounted with PBS-glycerol (1:1) 
or Aquamount Mountant (BHD Ltd., Poole, UK). The number 
oflymphocytes bound to various heart structures was determined 
from these preparations. 
mAbs and Fusion Proteins.  The characterization of two ham- 
ster anti-rat L-selectin mAbs, one blocking (HRL1) and the other 
one not blocking adhesion (HRL2), has been published (24, 25). 
The  generation of PVR-Ig and L-selectin-IgG fusion proteins 
has  also  been  documented  (24,  25).  Anti-MHC  class  II  (043, 
IgG1) antibody was from Sera-Lab Ltd. (Crawley Down, Sussex, 
UK). Anti-sLex mAb (CSLEX-1,  IgM) was  obtained from Dr. 
Paul Terasaki (University of California at Los Angeles, Los Ange- 
les,  CA), anti-sLea (CA19-9,  IgG1) from CIS Bio International 
(Gif-Sur-Yvette, France),  anti-Lewis  x (CD15,  IgM)  mAb from 
Immunotech  (Marseilles,  France),  and  anti-Lewis  a  (IgM)  from 
Ortho  Diagnostic  Systems  (Raritan,  NJ).  Anti-E-selectin anti- 
body (7A9, IgG1) was a kind gift from Walter Newman (Otsuka 
America Pharmaceutical Inc., Rockville, MD), and it was used as 
a negative control. Broad spectrum  Vibrio cholerea sialidase acting 
on  e~2-3,6,8-1inked  sialic  acid  was  purchased  from  Oxford 
GlycoSystems Ltd. (Abingdon, UK). 
ImmunohistochemicaI Stainings.  The  immunoperoxidase stain- 
ings for frozen sections were performed with routine specimens 
after acetone fixation for 10 min at 4~  The stainings with fusion 
proteins  were  performed  as  previously  described  (24,  25).  In 
short,  frozen sections were  fixed in  1%  paraformaldehyde, pH 
7.3, for 20 rain at 4~  followed by incubation in 100% methanol 
with 0.3% H202 to eliminate endogenous peroxidase for 20 rain 
at 4~  The sections were then washed in PBS and were incu- 
bated for 60 rain at 4~  with 1-10 ~g of either PVR.-Ig or L-selec- 
tin-IgG fusion proteins diluted in PBS containing 5% FCS. Then 
the sections were washed and incubated with biotinylated goat 
anti-human  IgG  (Zymed  Laboratories,  San  Francisco,  CA)  in 
PBS containing 5% FCS for 30 rain at 21~  The sections were 
incubated with 3-amino-9-ethyl carbatzole and H202 for 10 rain, 
washed,  counterstained  with  hematoxylin,  and  mounted  with 
Aquamount mountant (BDH Ltd.) for light microscopic analyses. 
Enzymatic Synthesis of sLex Oligosaccharides.  Synthesis of the Lex 
trisaccharide has been described previously (26). For construction 
of the monovalent sLex tetrasaccharide,  the divalent sLex decasac- 
charide,  and the tetravalent  sLex 22-saccharide  N-acetyllactosamine, 
the  hexasaccharide  Gal~-4GlcNAc[31-6(Gal[31-4GIcNAc[31-3) 
Gal[31-4GalNAc  (27)  and  the  tetradecasaccharide  Ga1131-3 
GlcNAc[31-6(Gal[31-4GIcNAcI31-3) Galt31-4GlcNAc[31-6  [Gal[31-4 
GlcNAc[31-6(Gal131-4GlcNAcJ31-3)GalJ31-4GlcNAc[31-3 ] Gal [31- 
4GIcNAc (28) were used, respectively, as primers. The acceptors 
were  first  ~x2,3-sialylated by incubating them exhaustively with 
CMP-NeuNAc and ~x2,3-sialyltransferase from human placenta. 
The  isolated, fully sialylated saccharides were then od,3 fucosy- 
lated exhaustively with GDP-Fuc and a partially purified prepara- 
tion  of human  milk cll,3-fucosyltransferase(s) (26).  The  sample 
sizes were estimated by UV absorption against external N-acetyl- 
glucosamine. The  characterization of the constructs was carried 
out by ion exchange chromatography, matrix-assisted laser des- 
orption ionization mass  spectrometry, and  one-dimensional 1H 
nuclear magnetic resonance spectroscopy at 500 MHz. 
Results 
Endothelium  in Rejecting  Cardiac  Transplants  Adheres More 
Lymphocytes than Normal Endothelium.  To analyze the role 
of lymphocyte extravasation during rejection episodes, we 
performed  MHC-incompatible  allogeneic transplantations 
between  inbred  rat  stains  DA  to  WF.  Control  syngeneic 
transplantations were performed within DA or WF strains 
1134  Inducible Sialyl Lewis  a and Lewis  x Expression during Inflammation Figure 1.  Binding oflymphocytes to endothelial structures in normal and transplanted heart tissue in the Stamper-Woodruffassay.  The microphoto- 
graphs have been taken so that the lymphocytes (round and black) are in focus and the underlying  (gray) tissue is slightly out of focus. Bound lymphocytes 
are marked by small black arrows. (a) Only very few lymphocytes are bound to the endocardium of normal hearts. (b) In the syngeneic grafts and in (c) al- 
lografts, the number of bound lymphocytes is also at a very low level. The same observation was made in arterioles; these structures in normal hearts (d) 
practically did not adhere lymphocytes at all, and the binding in syngeneic grafts (e) and allografts ~  was at a very low level. Venules (dashed  line) from 
normal hearts (g) and syngeneic grafts (h) adhered only a few lymphocytes, but on the contrary, the venules in the allografts (0 adhered an increased num- 
ber oflymphocytes.  Intermuscular capillaries adhered some lymphocytes in the normal tissue 0) and in the syngeneic grafts (k). (/) There was a clear en- 
hancement in the lymphocyte adherence to intermuscular capillaries  in the allografts.  A large number of cross and longitudinal sections of intermuscular 
capillaries  are seen in this panel, and only a few of the lymphocytes adhering to these structures are marked by arrows. Note that in all panels there are also 
some lymphocytes adhering directly on top of the myocardium that are not lying on top of any endothelial structures (a and l, white arrows). 
(from DA to  DA or from WF  to WF  strains), and normal 
hearts  (from DA and WF) were  used as negative controls. 
The hearts were removed on day 3 when the rejection had 
just  started,  frozen  sections  were  cut,  and  the  Stamper- 
Woodrufflymphocyte adhesion assay was performed. 
In  sections  prepared  from  syngeneic  grafts  of  normal 
hearts,  endothelium in the tissue sections prepared from al- 
lografts bound significantly more lymphocytes  than to  the 
endothelium  (Table  1  and  Fig.  1).  When  the  anatomical 
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location was analyzed in more detail, the endothelium was 
divided into several categories according to  the size of the 
vascular structure:  (a)  endocardium,  (b)  arterioles,  (c)  ven- 
ules,  and  (d)  intermuscular capillaries.  Lymphocyte  adhe- 
sion was assayed in these various compartments and, it was 
found to be increased onto the intermuscular capillaries and 
venules during rejection (Table 1  and Fig.  1). There was a 
constant low  background  binding of lymphocytes  to  the 
myocardium in all heart specimens. Table  1.  Number of In  Vitro-adherent  Lymphocytes  per One 
High-power Microscopic Field on Normal Hearts and on Syngeneic or 
Allogeneic Heart Grafts on Day 3 after Transplantation 
Normal  Syngraft  Allograft 
Total area  47.4  -  4.3  71.1  ___ 5.6  151.6  -  16.1 
Endocardium  0.1  +  0.1  2.1  -+ 0.7  2.8  +  1.3 
Arterioles  0.1  --+ 0.1  2.1  _+ 0.1  1.6  +  0.7 
Venules  5.2  +  0.4  7.6  +  0.5  12.2  _+  1.6 
Intermuscular 
capillaries  23.8  +  3.1  42.7  -+ 3.8  119.4  +  12.4 
Myocardiurn  17.3  +  0.0  16.6  --+  1.1  15.6  +  1.9 
The mean -+ SEM of seven independent experiments is presented. 
The  specificity of lymphocyte-endothelial  adhesion  was 
demonstrated  in several ways:  (a)  it was practically absent in 
syngeneic  grafts  or normal  nontreated  hearts  (Table  1);  (b) 
it was  not affected by the  origin of adherent  lymphocytes, 
i.e.,  both DA and WF  cells adhered  equally well to DA to 
WF  grafts  (data  not  shown);  and  (c)  it  was  inhibited  by 
treating the tissue sections with sialidase before adding lym- 
phocytes  (data not shown). 
De Novo Endothelial Reactivity with Anti-sLea and -sLex An- 
tibodies  and  L-selectin-Ig  Fusion  Protein  on  Rejecting  Cardiac 
Transplants.  The  data  presented  above  indicate  that  the 
inflammation associated with acute rejection induced proad- 
hesive properties  to the graft endothelium.  Since the selec- 
tin-mediated  rolling has  been  suggested  to  be  the  primary 
event in the cascade leading to leukocyte extravasation,  we 
focused on molecules putatively taking part  in the  genera- 
tion  of lymphocyte infiltration in  the  rejected heart  grafts. 
Figure 2.  Photomicrograph  of immunoperoxidase  stainings with antiohgosaccharide  mAbs and L-selectin-IgG fusion protein.  (a) Staining of normal 
heart tissue with anti-sLex antibody  revealed no reactivity.  (b) Anti-sLea antibody  staining of syngeneic graft remained  also negative. (c) Allograft tissue 
did not react with anti-sLea antibody  after siahdase treatment,  whereas in longitudinal  sections of venules in the allograft on day 3 after transplantation 
stained positively (d, brown)  with anti-sLea mAb. (e) A high power field of a capillary in the allograft reacting strongly with anti-sLex antibody. L-selectin- 
IgG fusion protein revealed no endothehal  reactivity in normal hearts (f) and, similarly, the negative control fusion protein PVR-Ig (g) did not react with 
the syngeneic graft. (h) On the contrary, capillaries and venules in the aUograft stained strongly with the fusion protein.  (0 A high power magnification of 
an endothelial cell staining strongly with the L-selectin-IgG fusion protein  lining a venule in an allografted heart.  ￿  100 in a, b, d,f, and h; ￿  in c, e, 
g, and i. 
1136  Inducible Sialyl Lewis  a and Lewis  x Expression during Inflammation L-selectin has at least three heavily glycosylated mucin-like 
protein  counterreceptors,  GlyCAM-1,  CD34,  and  MAd- 
CAM-1  (11-14).  In vitro assays have also pointed  out  the 
crucial role of sialylated,  fucosylated,  and sulfated oligosac- 
charides  in  L-selectin-dependent  adhesion  (6-10).  We 
therefore analyzed whether the endothelium would express 
sialyl  Lewis  epitopes  containing  ix2,3-sialylated  and  cil,3/ 
4-fucosylated  oligosaccharides.  As  shown  in  Table  2,  the 
endothelium  in normal hearts and syngeneic  grafts did not 
react  with  anti-sLea  and  -sLex  mAbs  (Ca19.9,  IgG1  and 
CSLEX-1,  IgM  respectively).  On  the  contrary,  all  endo- 
thelial  structures  in  allografts  undergoing  rejection  ex- 
pressed sLea and  sLex epitopes;  the venules  and  intermus- 
cular  capillaries  being  most  reactive  (Table  2  and  Fig.  2). 
Concomitantly,  isotype-matched  control  mAbs  against 
E-selectin  (IgG1), as well as Lex and Lea (IgM), were neg- 
ative  in  normal  hearts,  as well  as in  syngeneic  and  alloge- 
neic grafts (Table 2 and data not shown). 
Furthermmore,  stainings performed with L-selectin-IgG 
fusion  protein  also  demonstrate  endothelial  reactivity  in 
venules and  intermuscular  capillaries  only in allografts, but 
not  in  syngeneic  grafts or normal hearts  (Table  3  and  Fig. 
2).  In clear contrast,  stainings with  control  PVR-Ig  fusion 
protein  were  negative  in  all  heart  tissues.  The  reactivity 
with L-selectin-IgG fusion protein and anti-sLea and -sLex 
antibodies  could be removed from the allografts by prein- 
cubating  the  tissue  sections  with  sialidase  (Fig.  2  and  data 
not shown). 
Anti-L-Selectin  as  Well as Anti-sLea  and  -sLex Antibodies 
Inhibit  Lymphocyte  Adhesion  to  the  Endothelium  of Rejecting 
Cardiac  Transplants.  To  provide  evidence  for  the  direct 
role  of L-selectin  in  the  lymphocyte  adhesion  to  cardiac 
endothelium,  we performed  the  Stamper-Woodruff bind- 
ing  assay using lymphocytes incubated  with  anti-L-selectin 
mAbs before placing them into the binding assay. The lym- 
phocyte binding to syngeneic grafts was only slightly above 
the  control levels  (Table  1),  and this binding  could not be 
significantly  modified  by  anti-L-selectin,  -sLea,  or  -sLex 
antibodies  (data not shown). 
Figure  3.  Effect  of various mAbs on the lymphocyte adhesion to al- 
lograft endothelium. Lymphocyte pretreatment with a function-blocking 
anti-L-selectin mAb (HRL-1), as well as anti-sLea and anti-sLex pretreat- 
ment to allograft tissue reduced the lymphocyte adhesion significantly. 
The mean --- SEM of one representative experiment out of five is pre- 
sented. 
On the contrary, the anti-L-selectin mAb HRL-1, shown 
to  recognize  a  functional  epitope,  decreased  the  lympho- 
cyte  adherence  to  allograft  tissue  down  to  37%  compared 
to the nontreated  control (Fig. 3). Concomitantly,  HRL-2, 
which  is  a  non-function-blocking  anti-L-selectin  anti- 
body,  had  no  effect.  To  show  that  the  de  novo-induced 
endothelial  oligosaccharide  expression  on  allograft  endo- 
thelium  was  involved  in  the  increased  lymphocyte  adhe- 
sion, we used anti-sLea and -sLex mAbs as inhibitors of ad- 
hesion.  When  the  tissue  sections  prepared  from  the 
allografts were incubated  with  anti-sLea or -sLex antibod- 
ies,  the  lymphocyte  adhesion  to  aUografts decreased  down 
to  24  and  38%,  respectively  (Fig.  3).  When  the  two  ap- 
proaches were used simultaneously,  i.e.,  lymphocytes were 
treated with  the function-blocking  anti-L-selectin  HRL-1 
and  the  tissue  sections  were  treated  with  anti-sLea,  the 
lymphocyte  adhesion  was  decreased  to  background  levels 
(Fig.  3). As a negative  control,  the tissue sections were  in- 
cubated  with  an  isotype-matched  anti-MHC  class  lI anti- 
body, which  reacted with the  endothelium  but had no  ef- 
fect on the lymphocyte binding. 
Table 2.  Expression  of Lex, sLea, and sLex on Various Anatomical Structures on Normal Hearts and on Syngeneic or Allogeneic Heart Grafts 
on Day 3 after Transplantation 
Lewis  x  Sialyl Lewis  ~  Sialyl Lewis  x 
Normal  Syngraft  Allograft  Normal  Syngraft  AUograft  Normal  Syngraft  Allografi 
Endocardium 
Arterioles 
Venules 
Intermuscular 
capillaries 
Myocardium 
+  -  + 
+  -  _  + 
§247247  -  •  +§ 
++  -  _  + 
1137  Turunen et al. Table  3.  Reactivity of Various Anatomical Structures on Normal Hearts and on Syngeneic or Allogeneic  Heart Grafts on Day 3 after 
Transplantation  Stained with Either the Control PVR-Ig- or the L-section-Ig Fusion Protein 
PVP,-Ig fusion protein  L-selectin-Ig fusion protein 
Normal  Syngraft  Allograft  Normal  Syngraft  Allograft 
Endocardium 
Arterioles 
Venules 
Intermuscular 
capillaries 
Myocardium  w 
m 
++ 
++ 
Monovalent sLN 
Net~qAca2/3 Gal~I'4GIcNAc 
Divalent sLN 
Ne~/Aca2 / ~all31 "4GIr2gAc  1t 1  \ IGal  ~  1.4GIe2qA  c 
NI~qAca2  /3GLI [  ~  l'4Glclq Ac fl l / 
Tetravalent sLN 
NettNAc a2  /  3Oal~  1  "4GIcNAr ~  Lx  ~Glt1131.4GIcNAc  i~  I 
/ 3Oalj3  I'4GIcNAc  ~1/  x 
NeuNAca2  ~Gal[~  I-4GIcNAc 
NeuNAc~/  ~GIdI~I-~IeNAc[~ 1  / 
N~NAca2/~O~ 1  "4olr  ~1/ 
Monovalent sLex 
3Gal~ 1-4GlcNAc 
NeuNAca2 /  FttCal/3 
Divalent sI~x 
3O~fl~  1-4OlcNAc~ K, 
NeuNAca2 /  Focal/3  6Girl ~I.4GIcNAc 
3Gal~  I-4GIcNAc  p  ] / 
NeuNAca2 /  Ftcal/3 
Tetravalent sLex 
-~Gal  ~  I-4GIcNAc  ~  1\ 
NellNAcct2/~[~lcctl/3  6  ........  1  3  t~ pl-4Ulc~Acp 
3Gal  p  1-4GIcNAc ~  1  /  N 
Neu,N.Acr  x  6Gal BI-4GIcNAc 
/ 3Gall3 I-4GIcNAc ~  1\  / 
NeuNAca2  Fucal/3  6Oal ~I.4GIcNAc~I / 
4Glfl[31-4OlgNAc]31  / 
Neu.NAccc2/~F,acal/3 
Figure  4.  Primary  structures 
of the  enzymaticaUy synthetized 
ohgosaccharides  of the sLN  and 
sLex families, which were tested 
for  their  ability  to  inhibit lym- 
phocyte-endothelial interaction. 
All Enzymatically  Synthesized sLex-type Oligosaccharides In- 
hibit Lymphocyte Adhesion  to the Endothelium  of Rejecting Car- 
diac Transplants but  Tetravalent sLex is Most Potent.  Finally, 
we tested the possibility of inhibiting the lymphocyte adhe- 
sion  to  the  cardiac  endothelium  during  acute  rejection 
episodes  by oligosaccharides.  We generated the following 
family of oligosaccharides by enzyme-aided synthesis: mono- 
valent  sLex tetrasaccharide,  divalent sLex decasaccharide, 
and tetravalent sLex 22-mer oligosaccharide, as well as their 
nonfucosylated sialyl lactosamine analogues  (Fig.  4).  The 
structures of these  glycans were verifed by chromatogra- 
phy,  one-dimensional  nuclear  magnetic  resonance,  and 
mass spectroscopy. The lymphocytes were preincubated for 
30 rain with various concentrations of the oligosaccharides 
and used thereafter in the Stamper-Woodruffbinding assay 
in  the  incubation media.  These  oligosaccharides did  not 
significantly alter  the  lymphocyte binding  to  syngeneic 
grafts, which was only slightly above the binding to normal 
heart tissue  (Table  1 and data not shown).  On  the other 
hand, all members of the sLex family were effective in in- 
hibiting lymphocyte adhesion to cardiac  endothelium, but 
the tetravalent sLex was  clearly superior compared to the 
100" 
i  .~ 
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III  2O 
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Figure  5.  Effect  of various  enzymatically  synthetized oligosaccharide 
constructs on the lymphocyte adhesion to aUograft  endothelium.  While 
all the oligosaccharides in the sLex family reduced binding, the inhibitory 
capacity of tetravalent sLex was significantly superior to other sLex oli- 
gosaccharides. All the sLNs lacking fucose were without effect. The mean 
-+ SEM of one representative experiment out of three is presented. --0-, 
tetravalent sLN;  -B-,  divalent sLN;  -0-,  monovalent sLN;  -O-,  tet- 
ravalent sLex; -[]-, divalent sLex; -~-,  monovalent sLex. 
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nonfucosylated sLN glycans remained without effect. 
Discussion 
We show in this paper that normal cardiac endothelium 
does not express sLea or sLex oligosaccharides present in 
L-selectin  counterreceptors  and  concomitantly  does  not 
support  lymphocyte  adhesion.  On  the  contrary,  during 
acute graft rejection, the cardiac endothelium began to ex- 
press both of these sialylated Lewis epitopes and to support 
lymphocyte adhesion.  Furthermore,  the  cardiac  endothe- 
lium stains in a sialidase-sensitive  manner with the L-selec- 
tin-IgG fusion protein during acute rejection episodes. The 
lymphocyte adhesion  to  graft  endothelium was  inhibited 
by treating the  endothelium either with sialidase  or anti- 
sLea or -sLex mAbs. Adhesion was also inhibited by treat- 
ing  the  lymphocytes with  anti-L-selectin mAb  or  sLex- 
bearing  oligosaccharide  constructs.  All  this  points  to  the 
crucial role of L-selectin--sLea-, and sLex-dependent lym- 
phocyte extravasation into  cardiac  allografts  during  acute 
rejection. 
Acute  organ  allograft  rejections are  characterized by a 
heavy infiltration of lymphocytes (20, 21).  Since the hall- 
mark of rejection is lymphocytosis in the graft, the essential 
task in preventing rejection would be to prevent the entry 
of lymphocytes into the grafts.  A  number of studies have 
indicated that the level of expression of endothelial adhe- 
sion molecules intracellular adhesion molecule-I, vascular 
cell  adhesion  molecule-I,  and  E-selectin  increase  during 
cardiac rejection (29-32). Likewise, the direct use of anti- 
bodies against  these adhesion molecules or their counter- 
receptors has  demonstrated that  they are  involved in  the 
lymphocyte infiltration (33).  The current concept in lym- 
phocyte extravasation, however, is that the cells must first 
roll on the endothelium via a selectin-carbohydrate-medi- 
ated interaction before they can adhere with integrins (1-5, 
34, 35).  Since the majority of lymphocytes do not possess 
counterreceptors for E- or P-selectins (36,  37), we sought 
evidence for L-selectin being involved in the primary roll- 
ing leading to lymphocyte infiltration into the heart trans- 
plants. 
Endothelial expression of L-selectin counterreceptors is 
very restricted (38, 39). We and others have shown that the 
high endothelium in the peripheral but not in the mucosal 
lymph nodes  express sLex and sLea  oligosaccharides (15- 
17). In peripheral lymph nodes, the high endothelium sup- 
ports L-selectin-dependent lymphocyte adhesion, expresses 
specific glycoforms of CD34, and secretes GlyCAM-1  (11, 
13,  14).  The  routine  GlyCAM-1  glycoprotein from pe- 
ripheral  lymph  nodes  is  decorated  by  sulfated  sLex  oli- 
gosaccharides (40). 
Our  assays do  not  answer  whether the  sLea and  sLex 
epitopes on the endothelium are on protein or lipid back- 
bones,  but  they demonstrate  that the  expression of these 
epitopes is strongly upregulated during inflammation. How 
is then the sLea and sLex expression induced to endothelial 
cells? We  have  shown  that  cultured endothelial cells  ex- 
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press sLex and have several functional ot2,3 sialyl- and o~1,3 
fucosyltransferases, which are able to sialylate and fucosylate 
distal N-acetyl lactosamine sequences, thus generating sLex 
epitopes  (19).  These endothelial enzyme activities can be 
enhanced in vitro by inflammatory cytokines such as TNF 
(19).  Thus,  our previous  results  indicate  that  endothelial 
cells  have  the  machinery  for  generating  sialylated  Lex 
epitopes in an inflammation-regulated manner. A comple- 
mentary  mechanism  could  involve  passive  absorption  of 
sLea and sLex from blood circulation by endothelial cells 
(16),  but even this process should be inducible by inflam- 
mation. 
The question of rodent tissues  expressing sLex type of 
oligosaccharides is  a  controversial one.  There is  evidence 
that  rodent leukocytes do  not  express sLex (41).  Murine 
GlyCam-1 secreted by lymph node endothelium, however, 
does bear sulfated sLex epitopes  (40)  and we have previ- 
ously shown that peritubular capillary endothelium on rat 
kidney allografts  starts  to de novo express sLex during re- 
jection (18). So, it may well be that sLex-type oligosaccha- 
rides are not expressed on rodent leukocytes, or that they 
are modifications that do not react with the presently avail- 
able anti-sLex mAbs.  The sLex-type structures in the  en- 
dothelium of lymph nodes or inflamed tissues of these ani- 
mals, however, do react with the same mAbs. 
The induction of endothelial sialyl Lewis epitopes at sites 
of inflammation  and  their  crucial  role  in  L-selectin-de- 
pendent  lymphocyte extravasation  leads  to  the  tempting 
possibility of blocking the generation of inflammation with 
oligosaccharides. Some published reports show that mono- 
valent sLex tetrasaccharide is able to block the P-selectin- 
dependent accumulation of granulocytes in models involv- 
ing lung inflammation or cardiac reperfusion (42,  43).  In 
vitro data suggests also that oligosaccharide constructs bear- 
ing two sLex groups (divalent sLex structures) are five times 
better  inhibitors  of E-selectin-dependent  adhesion  com- 
pared to monovalent sLex (44,  45). Although the genera- 
tion  of very complex oligosaccharides  has  been  difficult, 
enzyme-aided synthesis makes it possible at this time (28). 
We  have  constructed enzymatically a  family of sLex oli- 
gosaccharides in quantities sufficient for in vitro binding as- 
says. We could show that the tetravalent sLex was clearly 
superior in  blocking the  lymphocyte adhesion  to  cardiac 
endothelium compared to mono- or divalent sLex. Quite 
small  concentrations (50 nM) were needed for the inhibi- 
tory effects, suggesting that the amounts of oligosaccharides 
required in preventing inflammation even in vivo will not 
be out of reach. 
Taken together, the present data show that endothelial 
sLea and sLex expression are strongly induced in endothe- 
lium at sites of inflammation, such as organ allograft rejec- 
tion. Furthermore, this expression of sialylated Lewis epitopes 
is correlated to L-selectin-dependent lymphocyte adhesion 
to endothelium as a prelude to extravasation. We predict 
that direct in vivo use of anti-sLea, -sLex,  or -L-selectin 
antibodies,  or  even better,  of competing  oligosaccharide 
constructs, will inhibit lymphocyte entry into allografts and 
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